Novartis stands behind Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy Read more
ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial Read more
Sanofi : Dupixent (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis Read more
GSK grants exclusive technology license for clinical-stage Ebola vaccines to Sabin Vaccine Institute Read more
Bayer and LANXESS to sell their stakes in Currenta to Macquarie Infrastructure and Real Assets Read more
Lilly Announces Positive Results for Emgality (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments Read more